-transparent.png){kind=logo}
We describe here biochemical and pharmacological effects of the beta-carboline ZK 93426 was compared with Ro 15-1788 and CGS 8216, two compounds previously described as BZ receptor antagonists. Certain effects of ZK 93426, Ro 15-1788 and CGS 8216 were quite similar (e.g., 3H-FNM displacement, "GABA ratio", "photo-shift"). In most pharmacological tests ZK 93426 and Ro 15-1788 lacked overt effects; Ro 15-1788 was a weak agonist in some paradigms, while ZK 93426 exhibited a potent proconflict effect but also a weak anticonvulsant effect. This interesting finding with ZK 93426 suggests that BZ receptor ligands may possess differential efficacy at BZ receptor subtypes. In contrast, CGS 8216 exhibited potent proconvulsant effects in several paradigms in addition to proconflict and pentylenetetrazol generalizing effects. ZK 93426, Ro 15-1788 and CGS 8216 were almost equally potent as antagonists of the effects of BZ receptor agonists, such as diazepam and lorazepam. However, ZK 93426 was the most potent inhibitor of the convulsions produced by the BZ receptor inverse agonist DMCM.
L H Jensen, and
E N Petersen, and
C Braestrup, and
T Honoré, and
W Kehr, and
D N Stephens, and
H Schneider, and
D Seidelmann, and
R Schmiechen
January 1988,
Psychopharmacology,
L H Jensen, and
E N Petersen, and
C Braestrup, and
T Honoré, and
W Kehr, and
D N Stephens, and
H Schneider, and
D Seidelmann, and
R Schmiechen
January 1989,
Psychopharmacology,
L H Jensen, and
E N Petersen, and
C Braestrup, and
T Honoré, and
W Kehr, and
D N Stephens, and
H Schneider, and
D Seidelmann, and
R Schmiechen
January 1986,
Journal of neural transmission,
L H Jensen, and
E N Petersen, and
C Braestrup, and
T Honoré, and
W Kehr, and
D N Stephens, and
H Schneider, and
D Seidelmann, and
R Schmiechen
September 1992,
Behavioral and neural biology,
L H Jensen, and
E N Petersen, and
C Braestrup, and
T Honoré, and
W Kehr, and
D N Stephens, and
H Schneider, and
D Seidelmann, and
R Schmiechen
January 1987,
Psychopharmacology,
L H Jensen, and
E N Petersen, and
C Braestrup, and
T Honoré, and
W Kehr, and
D N Stephens, and
H Schneider, and
D Seidelmann, and
R Schmiechen
January 1989,
Behavioural pharmacology,
L H Jensen, and
E N Petersen, and
C Braestrup, and
T Honoré, and
W Kehr, and
D N Stephens, and
H Schneider, and
D Seidelmann, and
R Schmiechen
January 1995,
Psychopharmacology,
L H Jensen, and
E N Petersen, and
C Braestrup, and
T Honoré, and
W Kehr, and
D N Stephens, and
H Schneider, and
D Seidelmann, and
R Schmiechen
February 1996,
Psychopharmacology,
L H Jensen, and
E N Petersen, and
C Braestrup, and
T Honoré, and
W Kehr, and
D N Stephens, and
H Schneider, and
D Seidelmann, and
R Schmiechen
January 1992,
Journal of psychopharmacology (Oxford, England),
L H Jensen, and
E N Petersen, and
C Braestrup, and
T Honoré, and
W Kehr, and
D N Stephens, and
H Schneider, and
D Seidelmann, and
R Schmiechen
March 1990,
Epilepsy research,
